https://www.businesswire.com/news/home/20210415005258/en/Merck-and-Ridgeback-Biotherapeutics-Provide-Update-on-Progress-of-Clinical-Development-Program-for-Molnupiravir-an-Investigational-Oral-Therapeutic-for-the-Treatment-of-Mild-to-Moderate-COVID-19
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for...
Merck and Ridgeback Biotherapeutics Update on Clinical Development Program for Molnupiravir, an Investigational Therapeutic for Treatment of COVID-19
ridgeback biotherapeuticsclinical developmentmerckprovideupdate